Intellia Therapeutics, Inc. (NASDAQ: NTLA)

$16.57 ▲ +1.26 (+8.23%)

As of Apr 22, 2026 03:59 PM

Sector: Healthcare Industry: Biotechnology CIK: 0001652130

Market Cap 1.66 Bn

P/E -4.01

P/S 24.52

Div. Yield 0.00

Add ratio to table...

About

Intellia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing CRISPR/Cas9-based therapies for genetic diseases. The company operates within the biotechnology sector, leveraging its proprietary CRISPR/Cas9 technology platform to address a range of genetic disorders. Intellia's approach involves using CRISPR/Cas9 to edit genes directly within the body, aiming to provide durable, potentially curative treatments for conditions that are currently difficult to treat with conventional therapies. Intellia generates...

Intellia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing CRISPR/Cas9-based therapies for genetic diseases. The company operates within the biotechnology sector, leveraging its proprietary CRISPR/Cas9 technology platform to address a range of genetic disorders. Intellia's approach involves using CRISPR/Cas9 to edit genes directly within the body, aiming to provide durable, potentially curative treatments for conditions that are currently difficult to treat with conventional therapies.

Intellia generates revenue through its research and development efforts, which are funded by a combination of collaboration agreements, public offerings, and at-the-market offerings. The company's primary products include nex-z and lonvo-z, which are in clinical development for hereditary angioedema (HAE). Intellia also has other programs in its pipeline, such as NTLA-3001, which is being wound down as part of its strategic restructuring. The company's customer base primarily consists of patients suffering from genetic diseases, as well as collaborators and partners in the biopharmaceutical industry.

• Research and Development: Intellia's research and development segment focuses on the development of CRISPR/Cas9-based therapies. Key products in this segment include nex-z and lonvo-z, which are aimed at treating hereditary angioedema (HAE). The company also has other programs in its pipeline, such as NTLA-3001, which is being wound down. This segment caters to the biopharmaceutical market, with a focus on providing innovative treatments for genetic diseases.

Intellia Therapeutics holds a significant position in the biotechnology industry, particularly in the field of gene editing. The company's competitive advantages include its proprietary CRISPR/Cas9 technology platform, which allows for precise gene editing within the body. This technology platform is a key differentiator, enabling Intellia to develop therapies that have the potential to provide durable, curative treatments for genetic diseases. The company's strategic restructuring and focus on high-value programs within its pipeline further strengthen its competitive position.

Intellia Therapeutics' customers include patients suffering from genetic diseases, as well as collaborators and partners in the biopharmaceutical industry. The company's therapies are designed to address unmet medical needs, providing potentially life-changing treatments for conditions that are currently difficult to treat. Intellia's focus on innovation and its proprietary technology platform position it as a leader in the development of CRISPR/Cas9-based therapies.

Investment thesis

Bull case

Intellia’s one‑time gene‑editing platform remains uniquely positioned to transform a series of orphan diseases that traditionally require chronic, high‑cost therapies. The ATTRv‑PN program, now cleared by the FDA to resume enrollment, is poised to generate early revenue streams through a first‑in‑class treatment that offers durable disease modification with a single infusion. The timing of the regulatory lift aligns with the company’s cash runway, allowing it to sustain operations through the anticipated data readout in the second half of 2026 and to prepare for a commercial launch in the first half of 2027. The company’s balanced capital structure, with roughly $670 million in cash and a readily available ATM facility, underpins this aggressive pipeline strategy and gives it breathing room to absorb the cost of the ongoing ATTR‑CM hold without immediate liquidity pressure.
The company’s focus on the ATTR‑CM indication, despite the current hold, offers a far larger commercial opportunity than the ATTRv‑PN program alone. While the heart‑related form of amyloidosis has a more aggressive disease trajectory and a higher unmet need, the potential market size is considerably larger, encompassing a broader patient population that is already underserved by existing therapies. Intellia’s data indicating a less than 1% incidence of Grade 4 liver enzyme elevations among over 650 patients provides a reassuring safety signal that may be persuasive to regulators once a robust mitigation plan is articulated. The company’s proactive engagement with the FDA, as evidenced by the clinical hold, demonstrates a willingness to cooperate and adapt, which could translate into a favorable risk–benefit assessment if the hold is lifted.
Lonvo‑z, the one‑time treatment for hereditary angioedema, has already completed enrollment and is on track to deliver topline results in mid‑2026. The therapeutic benefit of completely eliminating attacks would be a paradigm shift for a patient group that currently relies on episodic, costly therapies. With the company’s extensive experience in the ATTR platform, the manufacturing scale‑up and supply chain logistics for Lonvo‑z can likely be leveraged, reducing time‑to‑market costs. The company’s recent collaboration revenue increase, driven primarily by a partnership with a major biopharma, underscores its capacity to monetize data assets and potentially secure additional licensing revenue.
Intellia’s choice of a lipid‑nanoparticle (LNP) delivery system that is common across both nex‑z and lonvo‑z indicates an opportunity for platform synergies. By reusing the same delivery vehicle, the company can potentially lower manufacturing complexity and reduce regulatory hurdles associated with novel delivery components. This consolidation can translate into cost efficiencies, improving gross margins once the drugs enter the commercial phase. Moreover, the shared LNP platform may enable cross‑indication data sharing, which could accelerate the development timeline for future programs targeting other monogenic diseases.
The company's emphasis on the high mortality of ATTR amyloidosis signals a robust market narrative that resonates with payers and clinicians alike. By framing the therapy as a life‑extending intervention, Intellia aligns its value proposition with reimbursement models that prioritize durable outcomes over incremental symptom control. This positioning is likely to strengthen payer negotiations, especially in markets where chronic therapies are heavily scrutinized for cost effectiveness. The narrative also enhances investor confidence, as it underscores a clear differentiation from existing treatments that merely slow disease progression.

Intellia’s one‑time gene‑editing platform remains uniquely positioned to transform a series of orphan diseases that traditionally require chronic, high‑cost therapies. The ATTRv‑PN program, now cleared by the FDA to resume enrollment, is poised to generate early revenue streams through a first‑in‑class treatment that offers durable disease modification with a single infusion. The timing of the regulatory lift aligns with the company’s cash runway, allowing it to sustain operations through the anticipated data readout in the second half of 2026 and to prepare for a commercial launch in the first half of 2027. The company’s balanced capital structure, with roughly $670 million in cash and a readily available ATM facility, underpins this aggressive pipeline strategy and gives it breathing room to absorb the cost of the ongoing ATTR‑CM hold without immediate liquidity pressure.
The company’s focus on the ATTR‑CM indication, despite the current hold, offers a far larger commercial opportunity than the ATTRv‑PN program alone. While the heart‑related form of amyloidosis has a more aggressive disease trajectory and a higher unmet need, the potential market size is considerably larger, encompassing a broader patient population that is already underserved by existing therapies. Intellia’s data indicating a less than 1% incidence of Grade 4 liver enzyme elevations among over 650 patients provides a reassuring safety signal that may be persuasive to regulators once a robust mitigation plan is articulated. The company’s proactive engagement with the FDA, as evidenced by the clinical hold, demonstrates a willingness to cooperate and adapt, which could translate into a favorable risk–benefit assessment if the hold is lifted.
Lonvo‑z, the one‑time treatment for hereditary angioedema, has already completed enrollment and is on track to deliver topline results in mid‑2026. The therapeutic benefit of completely eliminating attacks would be a paradigm shift for a patient group that currently relies on episodic, costly therapies. With the company’s extensive experience in the ATTR platform, the manufacturing scale‑up and supply chain logistics for Lonvo‑z can likely be leveraged, reducing time‑to‑market costs. The company’s recent collaboration revenue increase, driven primarily by a partnership with a major biopharma, underscores its capacity to monetize data assets and potentially secure additional licensing revenue.
Intellia’s choice of a lipid‑nanoparticle (LNP) delivery system that is common across both nex‑z and lonvo‑z indicates an opportunity for platform synergies. By reusing the same delivery vehicle, the company can potentially lower manufacturing complexity and reduce regulatory hurdles associated with novel delivery components. This consolidation can translate into cost efficiencies, improving gross margins once the drugs enter the commercial phase. Moreover, the shared LNP platform may enable cross‑indication data sharing, which could accelerate the development timeline for future programs targeting other monogenic diseases.
The company's emphasis on the high mortality of ATTR amyloidosis signals a robust market narrative that resonates with payers and clinicians alike. By framing the therapy as a life‑extending intervention, Intellia aligns its value proposition with reimbursement models that prioritize durable outcomes over incremental symptom control. This positioning is likely to strengthen payer negotiations, especially in markets where chronic therapies are heavily scrutinized for cost effectiveness. The narrative also enhances investor confidence, as it underscores a clear differentiation from existing treatments that merely slow disease progression.

Bear case

The fatal liver event in the ATTR‑CM trial, coupled with the subsequent FDA clinical hold, raises a significant safety red flag that could erode confidence among regulators, clinicians, and payers. Even though the incidence of Grade 4 liver enzyme elevations is less than 1% in a large cohort, the severity of the event and the lack of a definitive causal link to the therapy may trigger extended scrutiny and more stringent post‑market surveillance requirements. The company’s evasive answers regarding comorbidities and potential causative factors may suggest insufficient data transparency, further unsettling stakeholders.
The persistence of the hold on the ATTR‑CM program, while the ATTRv‑PN trial proceeds, creates a discontinuity in the company’s pipeline that can dilute investor expectations. The ATTR‑CM indication, representing a larger market, remains in regulatory limbo, potentially postponing a substantial revenue stream that could have justified the company’s valuation. The uncertainty surrounding a viable mitigation plan increases the probability of a protracted hold or even a partial or full withdrawal from the market.
The company’s ability to recover from the hold is heavily dependent on the outcome of the comprehensive safety analysis, which is currently inconclusive. The risk that the FDA may demand additional pre‑clinical studies, or impose stringent post‑approval monitoring requirements, could increase development costs and delay commercial launch. In the worst case, regulatory action could compel the company to halt the ATTR‑CM program entirely, leading to a loss of investment and potential reputational damage.
Intellia’s cash runway, while sufficient until mid‑2027, is subject to the unpredictability of the ATTR‑CM hold and the time needed to complete additional trials or remedial actions. The company’s financial statements show a decline in R&D expenses but still record substantial operational costs that could be exacerbated by the hold. If the company cannot secure additional financing or partnerships, it may be forced to cut back on other pipeline programs, limiting future growth opportunities.
The competitive landscape for ATTR amyloidosis is intensifying, with multiple players already offering or developing therapies that target the same patient populations. Alnylam’s injectable Amvuttra, Pfizer’s Vyndaqel, and BridgeBio’s Attruby represent significant market entrants with established clinical data, marketing pipelines, and payer relationships. Intellia’s potential delay in launching ATTR‑CM may allow competitors to capture market share, diminishing the commercial viability of its therapy.

The fatal liver event in the ATTR‑CM trial, coupled with the subsequent FDA clinical hold, raises a significant safety red flag that could erode confidence among regulators, clinicians, and payers. Even though the incidence of Grade 4 liver enzyme elevations is less than 1% in a large cohort, the severity of the event and the lack of a definitive causal link to the therapy may trigger extended scrutiny and more stringent post‑market surveillance requirements. The company’s evasive answers regarding comorbidities and potential causative factors may suggest insufficient data transparency, further unsettling stakeholders.
The persistence of the hold on the ATTR‑CM program, while the ATTRv‑PN trial proceeds, creates a discontinuity in the company’s pipeline that can dilute investor expectations. The ATTR‑CM indication, representing a larger market, remains in regulatory limbo, potentially postponing a substantial revenue stream that could have justified the company’s valuation. The uncertainty surrounding a viable mitigation plan increases the probability of a protracted hold or even a partial or full withdrawal from the market.
The company’s ability to recover from the hold is heavily dependent on the outcome of the comprehensive safety analysis, which is currently inconclusive. The risk that the FDA may demand additional pre‑clinical studies, or impose stringent post‑approval monitoring requirements, could increase development costs and delay commercial launch. In the worst case, regulatory action could compel the company to halt the ATTR‑CM program entirely, leading to a loss of investment and potential reputational damage.
Intellia’s cash runway, while sufficient until mid‑2027, is subject to the unpredictability of the ATTR‑CM hold and the time needed to complete additional trials or remedial actions. The company’s financial statements show a decline in R&D expenses but still record substantial operational costs that could be exacerbated by the hold. If the company cannot secure additional financing or partnerships, it may be forced to cut back on other pipeline programs, limiting future growth opportunities.
The competitive landscape for ATTR amyloidosis is intensifying, with multiple players already offering or developing therapies that target the same patient populations. Alnylam’s injectable Amvuttra, Pfizer’s Vyndaqel, and BridgeBio’s Attruby represent significant market entrants with established clinical data, marketing pipelines, and payer relationships. Intellia’s potential delay in launching ATTR‑CM may allow competitors to capture market share, diminishing the commercial viability of its therapy.

Consolidation Items Breakdown of Revenue (2025)

Statement of Income Location, Balance Breakdown of Revenue (2025)

Peer comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	111.64 Bn	28.22	9.30	-
2	REGN	Regeneron Pharmaceuticals, Inc.	78.17 Bn	17.32	5.45	1.99 Bn
3	ALNY	Alnylam Pharmaceuticals, Inc.	40.41 Bn	146.87	12.83	-
4	RVMD	Revolution Medicines, Inc.	28.31 Bn	-25.07	34,108.71	-
5	ZLAB	Zai Lab Ltd	26.77 Bn	-152.75	110.41	0.20 Bn
6	MESO	Mesoblast Ltd	24.41 Bn	-191.25	1,419.53	0.12 Bn
7	RPRX	Royalty Pharma plc	21.27 Bn	27.64	8.94	8.95 Bn
8	MRNA	Moderna, Inc.	21.10 Bn	-7.46	10.85	0.59 Bn

Research Tools